Press Releases Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
196.52 ^USD	+0.52%		-2.32%	+11.67%

02-13	Biogen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-13-2026 10:30 AM
02-12	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…

Press Releases

02-11	Biogen Announces Board Chair Transition	GL
02-09	Biogen : Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China	PU
02-06	Biogen : Q4 and Full Year 2025 Biogen Earnings Presentation	PU
02-06	Biogen : Reports Fourth Quarter and Full Year 2025 Results	PU
02-06	Biogen : BiogenQ4 2025 Earnings Presentation FINAL	PU
02-06	Biogen : Q4 2025 Earnings Press Release FINAL	PU
02-05	Stoke Therapeutics to Present at the Guggenheim Emerging Outlook, Biotech Summit 2026	AQ
02-04	Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy	GL
02-04	Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy	AQ
01-28	Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options	GL
01-26	Biogen : FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review	PU
01-12	Biogen : at the J.P. Morgan 44th Annual Healthcare Conference	PU
01-12	Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy	GL
01-07	Biogen : to Report Fourth Quarter and Full Year 2025 Financial Results February 6, 2026	PU
01-06	Biogen : to Present at the 44th Annual J.P. Morgan Healthcare Conference	PU
01-06	Biogen : Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China	PU
12-22	Biogen : Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen	PU
12-22	The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS	GL
12-08	Biogen : “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List	PU
12-05	Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting	GL
12-05	Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting	AQ
12-03	Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025	PR
12-02	New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF	PR
11-28	Biogen : Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan	PU
11-25	Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Press Releases

Filters